322 related articles for article (PubMed ID: 12124334)
1. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
[TBL] [Abstract][Full Text] [Related]
2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
4. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
5. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth.
Liu N; Lapcevich RK; Underhill CB; Han Z; Gao F; Swartz G; Plum SM; Zhang L; Green SJ
Cancer Res; 2001 Feb; 61(3):1022-8. PubMed ID: 11221828
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
[TBL] [Abstract][Full Text] [Related]
7. Goniodomin A, an antifungal polyether macrolide, exhibits antiangiogenic activities via inhibition of actin reorganization in endothelial cells.
Abe M; Inoue D; Matsunaga K; Ohizumi Y; Ueda H; Asano T; Murakami M; Sato Y
J Cell Physiol; 2002 Jan; 190(1):109-16. PubMed ID: 11807817
[TBL] [Abstract][Full Text] [Related]
8. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities.
Sheu JR; Fu CC; Tsai ML; Chung WJ
Anticancer Res; 1998; 18(6A):4435-41. PubMed ID: 9891506
[TBL] [Abstract][Full Text] [Related]
9. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
10. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.
He GA; Luo JX; Zhang TY; Hu ZS; Wang FY
Biochem Biophys Res Commun; 2004 May; 318(2):354-60. PubMed ID: 15120609
[TBL] [Abstract][Full Text] [Related]
11. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.
Juarez JC; Guan X; Shipulina NV; Plunkett ML; Parry GC; Shaw DE; Zhang JC; Rabbani SA; McCrae KR; Mazar AP; Morgan WT; Doñate F
Cancer Res; 2002 Sep; 62(18):5344-50. PubMed ID: 12235005
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
Burres NS; Clement JJ
Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.
Mousa SA; Mohamed S; Wexler EJ; Kerr JS
Anticancer Res; 2005; 25(1A):197-206. PubMed ID: 15816539
[TBL] [Abstract][Full Text] [Related]
14. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
16. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
[TBL] [Abstract][Full Text] [Related]
17. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.
Ramesh R; Mhashilkar AM; Tanaka F; Saito Y; Branch CD; Sieger K; Mumm JB; Stewart AL; Boquoi A; Dumoutier L; Grimm EA; Renauld JC; Kotenko S; Chada S
Cancer Res; 2003 Aug; 63(16):5105-13. PubMed ID: 12941841
[TBL] [Abstract][Full Text] [Related]
18. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth.
He GA; Luo JX; Zhang TY; Wang FY; Li RF
Biochem Biophys Res Commun; 2003 Dec; 312(3):801-5. PubMed ID: 14680836
[TBL] [Abstract][Full Text] [Related]
19. Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor.
Park MJ; Park IC; Bae IJ; Seo KM; Lee SH; Hong SI; Eun CK; Zhang W; Rhee CH
Int J Oncol; 2003 Jun; 22(6):1271-6. PubMed ID: 12738993
[TBL] [Abstract][Full Text] [Related]
20. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
